Tigenix Sa (TGXSF) 1.1800 $TGXSF TiGenix Cx601 positive

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Tigenix Sa (TGXSF) 1.1800 $TGXSF

TiGenix Cx601 positive Phase III results to be presented at Digestive Disease Week in the USA
GlobeNewswire - Wed May 18, 12:08AM CDT
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, is proud to present the week 24 positive results from its Phase III ADMIRE-CD pivotal study of Cx601 at the 2016 Digestive Disease Week (DDW) in San Diego, California (USA).

TiGenix: TiGenix reports 2015 full year results
GlobeNewswire - Tue Apr 12, 12:10AM CDT
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, reported today its business and financial highlights for 2015 and post year-end events.

TiGenix Presents 24 Week Results of its Cx601 Phase III Trial at ECCO 2016
GlobeNewswire - Thu Mar 17, 1:10PM CDT
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today the presentation of the 24 week results from the Phase III ADMIRE-CD pivotal trial of Cx601 for complex perianal fistulas in Crohn's disease patients, in a plenary session at the 11th Annual Congress of the European Crohn's and Colitis Organisation (ECCO) in Amsterdam, The Netherlands.

TiGenix announces acceptance of Cx601 abstract for presentation at ECCO 2016 Congress
GlobeNewswire - Mon Jan 11, 12:05AM CST
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today that the abstract related to the positive results of the ADMIRE-CD pivotal Phase III trial of Cx601 for complex perianal fistulas in Crohn's disease patients after 24 weeks has been accepted for oral presentation at the upcoming 11th Annual Congress of the European Crohn's and Colitis Organisation (ECCO) to be held from the 16th to 19th March in Amsterdam, The Netherlands.

TiGenix participates in key conferences in the first half of 2016
GlobeNewswire - Fri Jan 08, 12:13AM CST
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today the key conferences in which it is going to participate during the first half of 2016.

TiGenix files Registration Statement for proposed initial public offering in the United States
Thomson Reuters ONE - Tue Dec 22, 3:30PM CST
Leuven (BELGIUM) - December 22, 2015, 22:30h CET - TiGenix NV (Euronext Brussels: TIG; the "Company" , an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today that it has filed a Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission for a proposed initial public offering of its American Depository Shares ("ADSs" to be listed on the NASDAQ Global Market in the United States. The number and price of the ADSs to be offered have not yet been determined.

TiGenix completes enrolment of its Phase I/II study in acute myocardial infarction
Thomson Reuters ONE - Thu Nov 19, 12:08AM CST
Leuven (BELGIUM) - 19th November 2015 - TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today that it has completed enrolment of its Phase II study in acute myocardial Infarction (CAREMI study).

Left Ventricular Dysfunction Pipeline Review, H2 2015 - 6 Companies & 8 Drug Profiles
M2 - Mon Oct 05, 6:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kp5dt2/left_ventricular) has announced the addition of the "Left Ventricular Dysfunction - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Left Ventricular Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Left Ventricular Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Amgen Inc. - Bayer AG - Innopharmax Inc. - RedHill Biopharma Ltd. - TiGenix NV Drug Profiles - BAY-1142524 - CAP-1001 - CAP-1002 - carvedilol CR - cimaglermin alfa - CTX-101 - omecamtiv mecarbil - Small Molecule to Target O2 Radical for Left Ventricular Dysfunction and Diabetic Complications For more information visit http://www.researchandmarkets.com/research/kp...entricular
RDHL: 16.07 (-0.22), AMGN: 173.66 (+0.99), ACOR: 24.72 (-0.27)

TiGenix Business and Financial Update for the First Half of 2015
GlobeNewswire - Tue Sep 15, 11:30AM CDT
TiGenix NV (Euronext Brussels:TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, today announced its Business and Financial Update for the first half of 2015 and recent significant events.

TiGenix : TiGenix to host webcast for its 2015 half-year results on 15 September
GlobeNewswire - Thu Sep 10, 12:10PM CDT
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, will announce its half-year results for 2015 on Tuesday 15 September 2015 at 17:45 CET.

Anal Fistula Global 2015 - Clinical Trial Overview of Top Institutes / Government
M2 - Tue Aug 11, 3:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b2lb6g/anal_fistula) has announced the addition of the "Anal Fistula Global Clinical Trials Review, H1, 2015" report to their offering. Our clinical trial report, Anal Fistula Global Clinical Trials Review, H1, 2015" provides data on the Anal Fistula clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Anal Fistula. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Anal Fistula. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies - TiGenix NV Clinical Trial Overview of Top Institutes / Government - Ahvaz Jundishapur University of Medical Sciences - Akershus University Hospital - Alexandria University - Azienda Ospedaliera San Giovanni Battista - French Society of Coloproctology - Hospital Universitario La Paz - Hospital Universitario Virgen del Rocio - Hyogo College Of Medicine - Kermanshah University of Medical Sciences - King Khalid University Hospital For more information visit http://www.researchandmarkets.com/research/b2...al_fistula

TiGenix obtains FDA's endorsement through Special Protocol Assessment for its Cx601 Phase III registration trial in the US
GlobeNewswire - Fri Aug 07, 12:04AM CDT
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic stem cells, announced today that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for its Phase III registration trial of Cx601 in the U.S. for the treatment of complex perianal fistulas in Crohn's disease patients.

TiGenix: Transparency Information
GlobeNewswire - Fri Jul 31, 12:06PM CDT
TiGenix NV (Euronext Brussels: TIG) publishes information in accordance with articles 15 and 18 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions (the Law) and the Royal Decree of February 14, 2008 regarding the publication of major holdings.

TiGenix: Dirk Buscher and Jose Terencio resign from TiGenix board of directors
GlobeNewswire - Fri Jul 31, 12:04PM CDT
TiGenix NV (Euronext Brussels: TIG) announced today that Dirk Buscher and Jose Terencio resigned from their position as board member, effective as of July 31, 2015.

TiGenix: TiGenix expands pipeline and enters the cardiology field with clinical-stage company acquisition
GlobeNewswire - Thu Jul 30, 12:08AM CDT
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic adipose-derived stem cells, announced today the acquisition of cardiology-focused cell therapy company Coretherapix S.L., currently owned by Genetrix S.L. Its lead programme, AlloCSC-01, is an allogeneic cardiac stem cell product currently in a Phase II clinical trial in acute myocardial infarction (AMI), with interim data expected in the second half of 2016. The product is also in pre-clinical development for another cardiac disease. This acquisition expands TiGenix pipeline into cardiology indications and is expected to be closed on July 31, 2015, subject to certain conditions precedent.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 220

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 342

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 297

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 494

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 258

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 344

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 423

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 562

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 585

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 354

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Breast Aesthetics: Embracing Natural Beauty

Updated Category News Views 467

Global Surgeons Advocate for Natural Breast Aesthetics In a groundbreaking initiative, a coalition of prominent plastic surgeons has introduced a new standard for breast augmentation emphasizing 'Natural Breast Beauty'. This initiative, presented at an international symposium in Milan, arose from increasing concerns regarding aesthetically unpleasing results and the...

Continue Reading
Pony AI Receives Strong Buy Ratings from Top Financial Firms

Updated Category News Views 189

Pony AI's Promising Future with Top Ratings Pony AI has recently come into the spotlight after receiving a positive assessment from two major financial institutions, Bank of America and Goldman Sachs. Both firms have initiated coverage on the company, marking it with a favorable ‘buy’ rating. Bank of America has set an ambitious price target of $18, indicating a...

Continue Reading
Rapport Therapeutics: Insights on Neuropsychiatry Conference Participation

Updated Category News Views 116

Rapport Therapeutics at the Neuropsychiatry Summit BOSTON and SAN DIEGO – Rapport Therapeutics, Inc. (NASDAQ: RAPP), a clinical-stage biotechnology company, is making headway in the realm of neurological and psychiatric disorders through its small molecule precision medicines. The company is gearing up to participate in the upcoming TD Cowen's 5th Annual Novel...

Continue Reading
Innovative Credit Card Security Solution by InventHelp Inventor

Updated Category News Views 228

Innovative Credit Card Security Solution An inventor has come up with a groundbreaking idea to guard credit and debit card users against unauthorized transactions. This invention, termed the CREDIT CARD SECURITY LOCK, aims to provide an extra layer of protection, ensuring that only the legitimate cardholder can access their funds. Revolutionizing Payment Security This...

Continue Reading
Polling Insights: Vance and Walz's Debate Performance Analyzed

Updated Category News Views 87

Debate Highlights Between Vance and Walz In a recent debate that captured public attention, Minnesota Governor Tim Walz and Senator J.D. Vance (R-Ohio) engaged in a spirited discussion that left many viewers with strong opinions. According to flash polls conducted by CNN, Vance emerged slightly ahead in the eyes of debate watchers. Polling Results Breakdown The debate was...

Continue Reading